Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NKTR-102 Clear all
Completed Phase 3 Interventional Results available

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101
View directory record Official record
Conditions
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
NKTR-102, Treatment of Physician's Choice (TPC)
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

NCT01663012
View directory record Official record
Conditions
Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)
Interventions
Etirinotecan pegol
Drug
Lead sponsor
Lawrence Recht
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

NCT01457118
View directory record Official record
Conditions
Malignant Solid Tumor
Interventions
NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2, NKTR-102 50 mg/m2
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

NCT00806156
View directory record Official record
Conditions
Tumor, Ovarian Cancer
Interventions
NKTR-102 q14d, NKTR-102 q21d
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
11
States / cities
Highland, California • Los Angeles, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

NCT00856375
View directory record Official record
Conditions
Colorectal Cancer
Interventions
NKTR-102, irinotecan
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
9
States / cities
Peoria, Arizona • Burbank, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01876446
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Pegylated Irinotecan, Pharmacological Study
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

NCT02312622
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
Interventions
Pegylated Irinotecan
Drug
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744
View directory record Official record
Conditions
Metastasis, Breast Cancer
Interventions
NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

NCT01991678
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
Interventions
145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

NCT00802945
View directory record Official record
Conditions
Tumor, Breast Cancer
Interventions
NKTR-102
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Rancho Mirage, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

NCT00598975
View directory record Official record
Conditions
Tumor, Colorectal Cancer
Interventions
NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Louisville, Kentucky • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 3, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

NCT01976143
View directory record Official record
Conditions
Advanced Cancer, Metastatic Solid Tumors
Interventions
NKTR-102
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 3, 2026, 5:37 PM EDT